Pacira BioSciences, Inc. $PCRX Stake Raised by Intech Investment Management LLC

Intech Investment Management LLC increased its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 164.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 166,715 shares of the company’s stock after acquiring an additional 103,593 shares during the period. Intech Investment Management LLC’s holdings in Pacira BioSciences were worth $4,315,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Hantz Financial Services Inc. lifted its stake in Pacira BioSciences by 127.3% in the 4th quarter. Hantz Financial Services Inc. now owns 2,573 shares of the company’s stock worth $67,000 after acquiring an additional 1,441 shares in the last quarter. Simplify Asset Management Inc. lifted its stake in Pacira BioSciences by 91.9% in the 4th quarter. Simplify Asset Management Inc. now owns 86,261 shares of the company’s stock worth $2,232,000 after acquiring an additional 41,315 shares in the last quarter. LSV Asset Management lifted its stake in Pacira BioSciences by 179.8% in the 4th quarter. LSV Asset Management now owns 319,800 shares of the company’s stock worth $8,276,000 after acquiring an additional 205,500 shares in the last quarter. Global Retirement Partners LLC lifted its stake in Pacira BioSciences by 479.4% in the 4th quarter. Global Retirement Partners LLC now owns 2,028 shares of the company’s stock worth $52,000 after acquiring an additional 1,678 shares in the last quarter. Finally, HighTower Advisors LLC lifted its stake in Pacira BioSciences by 82.0% in the 4th quarter. HighTower Advisors LLC now owns 23,972 shares of the company’s stock worth $620,000 after acquiring an additional 10,802 shares in the last quarter. 99.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on PCRX shares. Needham & Company LLC increased their price objective on Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, May 1st. Zacks Research raised Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 7th. Royal Bank Of Canada raised their price target on Pacira BioSciences from $22.00 to $24.00 and gave the stock a “sector perform” rating in a research note on Friday, May 1st. Wall Street Zen downgraded Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Finally, Barclays cut their price target on Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating for the company in a research note on Thursday, March 26th. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pacira BioSciences presently has a consensus rating of “Hold” and a consensus price target of $29.40.

Pacira BioSciences Stock Performance

Shares of NASDAQ PCRX opened at $23.22 on Monday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.35 and a current ratio of 4.73. The firm has a market cap of $913.71 million, a price-to-earnings ratio of 193.52 and a beta of 0.29. The business’s 50-day simple moving average is $23.58 and its 200-day simple moving average is $23.33. Pacira BioSciences, Inc. has a 52 week low of $18.80 and a 52 week high of $27.64.

Pacira BioSciences (NASDAQ:PCRX) last issued its quarterly earnings data on Thursday, April 30th. The company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). The company had revenue of $177.38 million for the quarter, compared to analyst estimates of $171.80 million. Pacira BioSciences had a net margin of 0.70% and a return on equity of 10.24%. The business’s revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.65 EPS. As a group, equities research analysts expect that Pacira BioSciences, Inc. will post 1.91 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Pacira BioSciences news, CFO Shawn Cross sold 12,941 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $25.16, for a total value of $325,595.56. Following the sale, the chief financial officer owned 105,341 shares of the company’s stock, valued at $2,650,379.56. This trade represents a 10.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jonathan Slonin sold 3,261 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $22.82, for a total value of $74,416.02. Following the completion of the sale, the insider directly owned 223,640 shares in the company, valued at $5,103,464.80. This trade represents a 1.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 28,261 shares of company stock worth $702,610 in the last ninety days. Insiders own 6.40% of the company’s stock.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.